Estonija - estonski - Ravimiamet

norameda uab - deksametasoon - tablett - 4mg 30tk; 4mg 100tk; 4mg 20tk

Europska Unija - estonski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, esafoxolaner, praziquantel - eprinomectin, combinations, , avermectins, antiparasitic products, insecticides and repellents - kassid - for cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. veterinaarravim on üksnes märgitud, kui kõik kolm gruppi on suunatud samal ajal.

Estonija - estonski - Ravimiamet

lex ano uab - deksametasoon - tablett - 4mg 20tk

Estonija - estonski - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 4mg 28tk; 4mg 56tk; 4mg 100tk

Estonija - estonski - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 20mg 10tk; 20mg 50tk; 20mg 30tk; 20mg 20tk

Europska Unija - estonski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Europska Unija - estonski - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5.

Estonija - estonski - Ravimiamet

fresenius kabi ab - elektrolüüdid - infusioonilahuse kontsentraat - 10ml 20tk

Europska Unija - estonski - EMA (European Medicines Agency)

sandoz gmbh - natalisumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Estonija - estonski - Ravimiamet

ideal trade links uab - bupivakaiin - süstelahus - 5mg 1ml 4ml 5tk; 5mg 1ml 4ml 15tk; 5mg 1ml 4ml 10tk